National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/17061

TDMS Study 96021-01 Pathology Tables

NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03
Route: GAVAGE                                                                                                     Time: 11:03:02

                                                          FINAL#4 RATS




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  35065-27-1

       Lock Date:  01/16/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include All

































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          98           86           98           98           98           80           
  Early Deaths                                                                                                                      
    Natural Death                                     11           15            8            9           15           11           
    Moribund Sacrifice                                18           23           17           22           18           19           
    Dosing Accident                                                                           1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                24           16           28           20           20           21           
    Natural Death                                                                             1                                     
                                                                                                                                    
  Animals Examined Microscopically                    53           54           53           53           53           51           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (53)         (54)         (53)         (53)         (53)         (50)         
   Intestine Large, Rectum                            (53)         (54)         (53)         (53)         (53)         (50)         
   Intestine Large, Cecum                             (53)         (54)         (53)         (53)         (53)         (50)         
      Leiomyoma                                        1 (2%)                                                                       
   Intestine Small, Duodenum                          (53)         (54)         (53)         (53)         (53)         (51)         
   Intestine Small, Jejunum                           (53)         (54)         (53)         (53)         (53)         (50)         
   Liver                                              (53)         (54)         (53)         (53)         (53)         (51)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)                   
      Cholangioma                                                                                          2 (4%)                   
      Hepatocellular Adenoma                                                                                            1 (2%)      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Mesentery                                                                    (1)                       (1)                       
      Carcinoma, Metastatic, Uterus                                                                        1 (100%)                 
   Oral Mucosa                                        (21)         (12)         (16)         (12)         (16)         (25)         
      Gingival, Squamous Cell Carcinoma                             2 (17%)                   1 (8%)                    1 (4%)      
   Pancreas                                           (53)         (54)         (53)         (53)         (53)         (51)         
   Salivary Glands                                    (51)         (52)         (53)         (52)         (53)         (51)         
   Stomach, Forestomach                               (53)         (54)         (53)         (53)         (53)         (51)         
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Stomach, Glandular                                 (53)         (54)         (53)         (53)         (53)         (51)         
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Tooth                                              (34)         (13)         (19)         (22)         (23)         (35)         
      Peridontal Tissue, Neurofibrosarcoma             1 (3%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (52)         (54)         (53)         (53)         (53)         (51)         
      Aorta, Hemangiosarcoma, Metastatic, Heart        1 (2%)                                                                       
   Heart                                              (52)         (54)         (53)         (53)         (53)         (51)         
      Hemangiosarcoma                                  1 (2%)                                                                       
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Schwannoma Malignant                                          1 (2%)                    1 (2%)       1 (2%)       1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (54)         (53)         (53)         (53)         (51)         
      Adenoma                                                                                 1 (2%)                                
   Adrenal Medulla                                    (53)         (54)         (53)         (53)         (53)         (51)         
      Pheochromocytoma Malignant                       1 (2%)       1 (2%)                                                          
      Pheochromocytoma Benign                          2 (4%)       1 (2%)       4 (8%)       4 (8%)       2 (4%)       2 (4%)      
      Bilateral, Pheochromocytoma Benign                                                                                1 (2%)      
   Islets, Pancreatic                                 (53)         (54)         (53)         (53)         (53)         (51)         
      Adenoma                                          1 (2%)                                                                       
      Carcinoma                                                                  1 (2%)                                             
   Parathyroid Gland                                  (49)         (46)         (50)         (47)         (46)         (48)         
      Adenoma                                                                                              2 (4%)                   
   Pituitary Gland                                    (53)         (54)         (53)         (53)         (53)         (50)         
      Carcinoma, Metastatic, Oral Mucosa                            1 (2%)                                                          
      Neurofibrosarcoma, Metastatic, Tooth             1 (2%)                                                                       
      Pars Distalis, Adenoma                          18 (34%)     19 (35%)     19 (36%)     19 (36%)     24 (45%)     11 (22%)     
      Pars Distalis, Carcinoma                                                                                          1 (2%)      
   Thyroid Gland                                      (51)         (52)         (53)         (53)         (53)         (51)         
      Bilateral, C-Cell, Adenoma                       2 (4%)       4 (8%)                                 5 (9%)                   
      C-Cell, Adenoma                                 14 (27%)      9 (17%)     17 (32%)     11 (21%)     17 (32%)      6 (12%)     
      C-Cell, Adenoma, Multiple                                                               1 (2%)                    1 (2%)      
      C-Cell, Carcinoma                                2 (4%)       2 (4%)       1 (2%)       1 (2%)       2 (4%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (51)         (52)         (53)         (51)         (50)         
      Carcinoma                                                     1 (2%)                                                          
      Carcinoma, Metastatic, Mammary Gland                                       1 (2%)                                             
   Ovary                                              (53)         (53)         (53)         (53)         (53)         (50)         
      Cystadenoma                                      1 (2%)                                                                       
      Granulosa Cell Tumor Malignant                                                          1 (2%)                                
      Granulosa Cell Tumor Benign                                                1 (2%)                                             
      Granulosa-Theca Tumor Benign                                               1 (2%)                                             
      Schwannoma Malignant                                                       1 (2%)                                             
   Uterus                                             (53)         (54)         (53)         (53)         (53)         (50)         
      Carcinoma                                                     1 (2%)       1 (2%)                    1 (2%)                   
      Leiomyosarcoma                                                                          3 (6%)                                
      Polyp Stromal                                    6 (11%)      9 (17%)      4 (8%)       6 (11%)      3 (6%)       2 (4%)      
      Polyp Stromal, Multiple                          1 (2%)                                                                       
      Schwannoma Malignant                                          1 (2%)                    1 (2%)                                
      Squamous Cell Carcinoma                                                    2 (4%)                                             
      Cervix, Carcinoma                                                          1 (2%)                                             
      Cervix, Schwannoma Malignant                                               1 (2%)                                             
      Cervix, Schwannoma Malignant, Metastatic,                                                                                     
           Vagina                                                                                                       1 (2%)      
      Cervix, Squamous Cell Carcinoma                               1 (2%)                                                          
   Vagina                                             (1)          (3)          (2)          (1)          (1)          (3)          
      Fibrosarcoma                                                  2 (67%)                                                         
      Fibrous Histiocytoma, Metastatic, Skin                                                               1 (100%)                 
      Sarcoma                                                       1 (33%)                                                         
      Schwannoma Malignant                             1 (100%)                                                         3 (100%)    
      Squamous Cell Carcinoma                                                    1 (50%)      1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (54)         (53)         (53)         (53)         (51)         
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Lipoma                                           1 (2%)                                                                       
   Lymph Node                                         (3)          (3)          (3)          (2)          (5)          (6)          
      Deep Cervical, Carcinoma, Metastatic,                                                                                         
          Thyroid Gland                                                                                    1 (20%)                  
      Mediastinal, Carcinoma, Metastatic, Uterus                                                           1 (20%)                  
      Mediastinal, Histiocytic Sarcoma                                                        1 (50%)                               
   Lymph Node, Mandibular                             (51)         (52)         (53)         (51)         (53)         (51)         
   Lymph Node, Mesenteric                             (52)         (54)         (53)         (53)         (53)         (51)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Spleen                                             (53)         (54)         (53)         (53)         (53)         (51)         
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Thymus                                             (48)         (53)         (52)         (53)         (53)         (47)         
      Hemangiosarcoma, Metastatic, Heart               1 (2%)                                                                       
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (54)         (53)         (53)         (53)         (51)         
      Adenoma                                          1 (2%)                    1 (2%)       1 (2%)       3 (6%)       2 (4%)      
      Adenoma, Multiple                                1 (2%)                                                                       
      Carcinoma                                        8 (15%)      6 (11%)      7 (13%)      4 (8%)       6 (11%)      2 (4%)      
      Carcinoma, Multiple                                                                     1 (2%)                                
      Fibroadenoma                                    22 (42%)     21 (39%)     22 (42%)     22 (42%)     27 (51%)     24 (47%)     
      Fibroadenoma, Multiple                          19 (36%)     13 (24%)     14 (26%)     13 (25%)     12 (23%)      8 (16%)     
   Skin                                               (53)         (54)         (53)         (53)         (53)         (51)         
      Basal Cell Adenoma                                                                                   1 (2%)                   
      Basal Cell Carcinoma                                          1 (2%)                                              1 (2%)      
      Fibroma                                                                    2 (4%)       1 (2%)       1 (2%)                   
      Fibrosarcoma                                                  1 (2%)                                 1 (2%)                   
      Fibrous Histiocytoma                                                       1 (2%)                    1 (2%)                   
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Keratoacanthoma                                               1 (2%)                    1 (2%)                                
      Lipoma                                                                     1 (2%)                                             
      Sarcoma                                                       1 (2%)                                                          
      Schwannoma Malignant                                                                                              1 (2%)      
      Schwannoma Malignant, Metastatic, Vagina         1 (2%)                                                                       
      Squamous Cell Papilloma                                                                              1 (2%)                   
      Subcutaneous Tissue, Sarcoma                                               1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (54)         (53)         (53)         (53)         (51)         
      Astrocytoma Malignant                                                                   1 (2%)                                
      Carcinoma, Metastatic, Pituitary Gland                                                                            1 (2%)      
      Carcinoma, Metastatic, Oral Mucosa                            1 (2%)                                                          
      Neurofibrosarcoma, Metastatic, Tooth             1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (52)         (54)         (53)         (53)         (53)         (51)         
      Alveolar/Bronchiolar Adenoma                     1 (2%)                                              2 (4%)                   
      Basal Cell Carcinoma, Metastatic, Skin                                                                            1 (2%)      
      Carcinoma, Metastatic, Mammary Gland                          1 (2%)                                 1 (2%)       1 (2%)      
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)                   
      Carcinoma, Metastatic, Oral Mucosa                            1 (2%)                                                          
      Fibrous Histiocytoma, Metastatic, Skin                                     1 (2%)                                             
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Mediastinum, Hemangiosarcoma, Metastatic,                                                                                     
           Heart                                       1 (2%)                                                                       
   Nose                                               (53)         (54)         (53)         (53)         (53)         (51)         
   Trachea                                            (52)         (54)         (53)         (53)         (53)         (51)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (54)         (53)         (53)         (52)         (51)         
      Neurofibrosarcoma, Metastatic, Tooth             1 (2%)                                                                       
   Harderian Gland                                    (53)         (54)         (53)         (53)         (53)         (49)         
      Carcinoma, Metastatic, Oral Mucosa                            1 (2%)                                                          
      Neurofibrosarcoma, Metastatic, Tooth             1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (54)         (53)         (53)         (53)         (51)         
      Carcinoma, Metastatic, Mammary Gland                                                                              1 (2%)      
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Nephroblastoma                                                                          1 (2%)                                
      Stromal Nephroma                                              1 (2%)                                              1 (2%)      
      Bilateral, Renal Tubule, Carcinoma                                                                                1 (2%)      
      Renal Tubule, Adenoma                                                      1 (2%)                                             
   Urinary Bladder                                    (53)         (53)         (53)         (53)         (53)         (50)         
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(53)        *(54)        *(53)        *(53)        *(53)        *(51)         
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Leukemia Mononuclear                             1 (2%)                                                                       
      Lymphoma Malignant                               2 (4%)                                              3 (6%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            52          51          49          48          51          48               
     Total Primary Neoplasms                          108         100         105          97         117          70               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 50          41          45          46          49          40               
     Total Benign Neoplasms                            91          77          87          80         102          58               
                                                                                                                                    
   Total Animals with Malignant Neoplasms              12          20          16          14          14          11               
     Total Malignant Neoplasms                         17          23          18          17          15          12               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              3           2           2                       4           4               
     Total Metastatic Neoplasm                          8           5           2                       8           5               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                3000 UG/                                                                         
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50                                                                            
  Early Deaths                                                                                                                      
    Natural Death                                     14                                                                            
    Moribund Sacrifice                                16                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                20                                                                            
                                                                                                                                    
  Animals Examined Microscopically                    50                                                                            
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Small, Jejunum                           (49)                                                                          
      Fibrosarcoma                                     1 (2%)                                                                       
   Liver                                              (50)                                                                          
      Cholangioma                                      1 (2%)                                                                       
      Cholangioma, Multiple                            1 (2%)                                                                       
   Pancreas                                           (50)                                                                          
      Acinus, Adenoma                                  1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)                                                                          
      Fibrous Histiocytoma, Metastatic, Skin           1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Medulla                                    (50)                                                                          
      Pheochromocytoma Benign                          6 (12%)                                                                      
   Islets, Pancreatic                                 (50)                                                                          
      Adenoma                                          1 (2%)                                                                       
      Carcinoma                                        1 (2%)                                                                       
   Parathyroid Gland                                  (45)                                                                          
      Adenoma                                          1 (2%)                                                                       
   Pituitary Gland                                    (50)                                                                          
      Pars Distalis, Adenoma                          23 (46%)                                                                      
      Pars Distalis, Carcinoma                         1 (2%)                                                                       
   Thyroid Gland                                      (49)                                                                          
      C-Cell, Adenoma                                 18 (37%)                                                                      
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                3000 UG/                                                                         
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - cont                                                                                                             
      C-Cell, Carcinoma                                3 (6%)                                                                       
      Follicular Cell, Adenoma                         2 (4%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (49)                                                                          
      Cystadenoma                                      1 (2%)                                                                       
      Granulosa-Theca Tumor Benign                     1 (2%)                                                                       
   Uterus                                             (49)                                                                          
      Carcinoma                                        1 (2%)                                                                       
      Polyp Stromal                                    4 (8%)                                                                       
      Cervix, Schwannoma Malignant                     1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)                                                                          
      Carcinoma                                       10 (20%)                                                                      
      Fibroadenoma                                    16 (32%)                                                                      
      Fibroadenoma, Multiple                          14 (28%)                                                                      
   Skin                                               (50)                                                                          
      Basal Cell Carcinoma                             1 (2%)                                                                       
      Fibroma                                          2 (4%)                                                                       
      Fibrosarcoma                                     4 (8%)                                                                       
      Fibrous Histiocytoma                             1 (2%)                                                                       
      Schwannoma Malignant                             1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                3000 UG/                                                                         
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)                                                                          
      Schwannoma Malignant, Metastatic, Skin           1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)                                                                          
      Carcinoma, Metastatic, Pituitary Gland           1 (2%)                                                                       
      Meninges, Sarcoma                                1 (2%)                                                                       
      Meninges, Schwannoma Malignant, Metastatic,                                                                                   
           Skin                                        1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)                                                                          
      Carcinoma, Metastatic, Mammary Gland             1 (2%)                                                                       
      Fibrous Histiocytoma, Metastatic, Skin           1 (2%)                                                                       
   Nose                                               (50)                                                                          
      Basal Cell Carcinoma, Metastatic, Skin           1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (50)                                                                          
      Optic Nerve, Schwannoma Malignant,                                                                                            
          Metastatic, Skin                             1 (2%)                                                                       
   Harderian Gland                                    (50)                                                                          
      Schwannoma Malignant, Metastatic, Skin           1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)                                                                          
      Fibrous Histiocytoma, Metastatic, Skin           1 (2%)                                                                       
      Stromal Nephroma                                 1 (2%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 12/15/03  
Route: GAVAGE                                                                                                     Time: 11:03:02  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                3000 UG/                                                                         
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            49                                                                           
     Total Primary Neoplasms                          119                                                                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                 44                                                                           
     Total Benign Neoplasms                            92                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              23                                                                           
     Total Malignant Neoplasms                         27                                                                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              5                                                                           
     Total Metastatic Neoplasm                         10                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.